guest ::
| Home > Publications Database > Immune response in COVID-19: what is next? > print |
| 001 | 164055 | ||
| 005 | 20241203165108.0 | ||
| 024 | 7 | _ | |a 10.1038/s41418-022-01015-x |2 doi |
| 024 | 7 | _ | |a pmid:35581387 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9110941 |2 pmc |
| 024 | 7 | _ | |a 1350-9047 |2 ISSN |
| 024 | 7 | _ | |a 1476-5403 |2 ISSN |
| 024 | 7 | _ | |a altmetric:128409180 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00718 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Li, Qing |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Immune response in COVID-19: what is next? |
| 260 | _ | _ | |a London |c 2022 |b Macmillan |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1733229641_30590 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a (CC BY) |
| 520 | _ | _ | |a The coronavirus disease 2019 (COVID-19) has been a global pandemic for more than 2 years and it still impacts our daily lifestyle and quality in unprecedented ways. A better understanding of immunity and its regulation in response to SARS-CoV-2 infection is urgently needed. Based on the current literature, we review here the various virus mutations and the evolving disease manifestations along with the alterations of immune responses with specific focuses on the innate immune response, neutrophil extracellular traps, humoral immunity, and cellular immunity. Different types of vaccines were compared and analyzed based on their unique properties to elicit specific immunity. Various therapeutic strategies such as antibody, anti-viral medications and inflammation control were discussed. We predict that with the available and continuously emerging new technologies, more powerful vaccines and administration schedules, more effective medications and better public health measures, the COVID-19 pandemic will be under control in the near future. |
| 536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 0 |
| 536 | _ | _ | |a 354 - Disease Prevention and Healthy Aging (POF4-354) |0 G:(DE-HGF)POF4-354 |c POF4-354 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 2 | |a COVID-19 |2 MeSH |
| 650 | _ | 2 | |a COVID-19 Vaccines |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Immunity, Innate |2 MeSH |
| 650 | _ | 2 | |a Pandemics: prevention & control |2 MeSH |
| 650 | _ | 2 | |a SARS-CoV-2 |2 MeSH |
| 700 | 1 | _ | |a Wang, Ying |0 0000-0002-2571-9367 |b 1 |
| 700 | 1 | _ | |a Sun, Qiang |b 2 |
| 700 | 1 | _ | |a Knopf, Jasmin |0 0000-0003-2922-9370 |b 3 |
| 700 | 1 | _ | |a Herrmann, Martin |0 0000-0002-0258-2484 |b 4 |
| 700 | 1 | _ | |a Lin, Liangyu |0 0000-0003-4312-8955 |b 5 |
| 700 | 1 | _ | |a Jiang, Jingting |0 0000-0002-3128-9762 |b 6 |
| 700 | 1 | _ | |a Shao, Changshun |0 0000-0003-2618-9342 |b 7 |
| 700 | 1 | _ | |a Li, Peishan |0 0000-0002-6881-396X |b 8 |
| 700 | 1 | _ | |a He, Xiaozhou |b 9 |
| 700 | 1 | _ | |a Hua, Fei |b 10 |
| 700 | 1 | _ | |a Niu, Zubiao |b 11 |
| 700 | 1 | _ | |a Ma, Chaobing |b 12 |
| 700 | 1 | _ | |a Zhu, Yichao |b 13 |
| 700 | 1 | _ | |a Ippolito, Giuseppe |b 14 |
| 700 | 1 | _ | |a Piacentini, Mauro |b 15 |
| 700 | 1 | _ | |a Estaquier, Jerome |0 0000-0002-9432-8044 |b 16 |
| 700 | 1 | _ | |a Melino, Sonia |b 17 |
| 700 | 1 | _ | |a Weiss, Felix Daniel |0 0000-0003-0228-5081 |b 18 |
| 700 | 1 | _ | |a Andreano, Emanuele |0 0000-0003-0088-5788 |b 19 |
| 700 | 1 | _ | |a Latz, Eicke |0 P:(DE-2719)2000062 |b 20 |
| 700 | 1 | _ | |a Schultze, Joachim |0 P:(DE-2719)2811660 |b 21 |
| 700 | 1 | _ | |a Rappuoli, Rino |b 22 |
| 700 | 1 | _ | |a Mantovani, Alberto |0 0000-0001-5578-236X |b 23 |
| 700 | 1 | _ | |a Mak, Tak Wah |b 24 |
| 700 | 1 | _ | |a Melino, Gerry |0 P:(DE-2719)9001390 |b 25 |
| 700 | 1 | _ | |a Shi, Yufang |0 0000-0001-8964-319X |b 26 |
| 773 | _ | _ | |a 10.1038/s41418-022-01015-x |0 PERI:(DE-600)1496681-5 |p 1107-1122 |t Cell death and differentiation |v 29 |y 2022 |x 1350-9047 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/164055/files/DZNE-2022-00718.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/164055/files/DZNE-2022-00718.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:164055 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 20 |6 P:(DE-2719)2000062 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2811660 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)9001390 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 1 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CELL DEATH DIFFER : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b CELL DEATH DIFFER : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-30 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-30 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-30 |
| 920 | 1 | _ | |0 I:(DE-2719)1013024 |k AG Latz |l Innate Immunity in Neurodegeneration |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000018 |k AG Nicotera |l Synaptic Connectivity and Neurodegeneration |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1013038 |k AG Schultze |l Clinical Single Cell Omics (CSCO) / Systems Medicine |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1013024 |
| 980 | _ | _ | |a I:(DE-2719)5000018 |
| 980 | _ | _ | |a I:(DE-2719)1013038 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|